Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update
March 12, 2020 16:05 ET
|
Harpoon Therapeutics
Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in upfront/near-term...
Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update
March 05, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
February 20, 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference
November 26, 2019 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
November 12, 2019 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 06, 2019 16:05 ET
|
Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment of prostate and ovarian...
Telix Pharmaceuticals and GE Healthcare: Maximising 68Ga Supply for Prostate Cancer Imaging
October 13, 2019 19:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutical company focused on the development of...
Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
August 07, 2019 20:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Telix Pharmaceuticals and German Cancer Research Center (DKFZ) Enter into Collaboration and Option Agreement for Image-Guided Prostate Surgery
August 04, 2019 20:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and HEIDELBERG, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused...
Telix Pharmaceuticals y Grupo RPH firman acuerdo de fabricación y distribución en América Latina
July 02, 2019 20:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia y PORTO ALEGRE, Brasil, July 02, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, la “Compañía”), una compañía biofarmacéutica en fase-clínica,...